Sartorius Stedim grew third-quarter sales 7.4% in constant currencies before tariff compensation to customers. Underlying EBITDA margin was 31.1% versus 31.3% a year earlier, which was in line with company-compiled consensus. Management confirmed full-year guidance.
SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.
The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Price/Earnings (Normalized) | 53.94 | 17.63 | 29.33 |
Price/Book Value | 4.95 | 2.05 | 6.81 |
Price/Sales | 6.97 | 2.93 | 6.84 |
Price/Cash Flow | 34.44 | 13.59 | 26.56 |
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Quick Ratio | 0.48 | 0.99 | 1.41 |
Current Ratio | 1.16 | 1.69 | 2.05 |
Interest Coverage | 4.24 | 7.22 | 16.08 |
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Return on Assets (Normalized) | 5.40% | 4.75% | 13.27% |
Return on Equity (Normalized) | 10.62% | 8.32% | 24.92% |
Return on Invested Capital (Normalized) | 7.74% | 6.65% | 16.95% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| LOCK|K##&>@ht | LOCK|b^n | $151B | |||
| Becton Dickinson & Co
BDX
| LOCK|bpX | LOCK|zFYgT | $53B | |||
| ResMed Inc
RMD
| LOCK|n@$C?@W% | LOCK|<yCw | $35B | |||
| Alcon Inc
ALC
| LOCK|LQ?$YR% | LOCK|hb?P> | $33B | |||
| Medline Inc Ordinary Shares - Class A
MDLN
| LOCK|&$&mDM | LOCK|&<z%D | $31B | |||
| West Pharmaceutical Services Inc
WST
| LOCK|qT!d%#M | LOCK|h$d | $28B | |||
| Solventum Corp
SOLV
| LOCK|rQ#mnm | LOCK|WM | $15B | |||
| Baxter International Inc
BAX
| LOCK|j$ | LOCK|s?LS@ | $13B | |||
| Repligen Corp
RGEN
| LOCK|z!mfBWD! | LOCK|cNHRw | $11B | |||
| The Cooper Companies Inc
COO
| LOCK|M<&HJX% | LOCK|zGtvp | $11B |
United States